![Eric Venker](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Eric Venker
Amministratore Delegato presso
IMMUNOVANT, INC.
Patrimonio netto: 57 M $ in data 31/05/2026
Profilo
Attualmente, Eric Venker è co-presidente e direttore operativo di Roivant Sciences Ltd., presidente e direttore operativo di Roivant Sciences, Inc. e co-presidente e direttore operativo di Roivant Sciences GmbH (entrambi sono filiali di Roivant Sciences Ltd.) e co-presidente e direttore operativo di Montes Archimedes Acquisition Corp. Eric Venker è anche nel consiglio di Arbutus Biopharma Corp., Sio Gene Therapies, Inc., Aruvant Sciences, Inc. e Immunovant, Inc. In precedenza ha ricoperto la posizione di presidente del Consiglio di qualità del personale presso il Columbia University Medical Center. Eric Venker ha ricevuto un dottorato dalla Yale School of Medicine e un dottorato dal St. Louis College of Pharmacy.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 22/05/2026 | 1.613.063 ( 0,22% ) | 48 M $ | 31/05/2026 | |
IMMUNOVANT INC 0,12% | 07/04/2026 | 251.813 ( 0,12% ) | 8 M $ | 31/05/2026 |
Posizioni attive di Eric Venker
| Società | Posizione | Inizio |
|---|---|---|
| IMMUNOVANT, INC. | Amministratore Delegato | 21/04/2025 |
| ROIVANT SCIENCES LTD. | Presidente | 01/01/2021 |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Presidente | 01/01/2021 |
Aruvant Sciences, Inc.
 Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning | Direttore/Membro del Consiglio | - |
Roivant Sciences GmbH
 Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Develops and markets biopharmaceutical products | Presidente | 01/01/2018 |
Roivant Social Ventures, Inc.
 Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. is a not-for-profit social impact organization dedicated to advancing health equity by applying private sector strategies to biopharma innovation and healthcare delivery. The private company is based in New York, NY. The company focuses on ensuring equitable access to medicines and medical care regardless of geography, wealth, or insurance status by investing in early-stage companies developing therapies for underserved patient populations, incubating healthcare-focused social entrepreneurs, and embedding drug development education in academic institutions through fellowships and internships to promote diversity in the biopharma industry and clinical trials. Roivant Social Ventures also partners with companies, institutes, and organizations to create systemic improvements in healthcare access and delivery, with key focus areas including gene therapy access, increasing diversity in clinical trials, and fostering diversity, equity, and inclusion opportunities for future biopharma leaders. Lindsay Androski has been the CEO of the company since 2016. | Direttore/Membro del Consiglio | 01/01/2014 |
Precedenti posizioni note di Eric Venker
| Società | Posizione | Fine |
|---|---|---|
| SIO GENE THERAPIES INC. | Direttore/Membro del Consiglio | 05/04/2023 |
| ARBUTUS BIOPHARMA CORPORATION | Direttore/Membro del Consiglio | 25/05/2022 |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Amministratore Delegato | 01/01/2015 |
| ░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░ ░░░░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formazione di Eric Venker
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
19
Relazioni di 1° grado
12
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 12 |
|---|---|
Arbutus Biopharma Corp.
 Arbutus Biopharma Corp. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics which targets viral diseases | Health Technology |
Roivant Sciences Ltd.
 Roivant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company through its subsidiaries develops restorative therapies for autoimmune diseases | Health Technology |
St. Louis College of Pharmacy
 St. Louis College of Pharmacy Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Columbia University Medical Center
 Columbia University Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale School of Medicine
 Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roivant Sciences GmbH
Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Develops and markets biopharmaceutical products | Health Technology |
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops gene therapies to treat neurodegenerative diseases | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Health Technology |
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning | Health Technology |
Immunovant, Inc.
 Immunovant, Inc. BiotechnologyHealth Technology Develops restorative therapies for autoimmune diseases | Health Technology |
Montes Archimedes Acquisition Corp.
 Montes Archimedes Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Roivant Social Ventures, Inc.
Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. is a not-for-profit social impact organization dedicated to advancing health equity by applying private sector strategies to biopharma innovation and healthcare delivery. The private company is based in New York, NY. The company focuses on ensuring equitable access to medicines and medical care regardless of geography, wealth, or insurance status by investing in early-stage companies developing therapies for underserved patient populations, incubating healthcare-focused social entrepreneurs, and embedding drug development education in academic institutions through fellowships and internships to promote diversity in the biopharma industry and clinical trials. Roivant Social Ventures also partners with companies, institutes, and organizations to create systemic improvements in healthcare access and delivery, with key focus areas including gene therapy access, increasing diversity in clinical trials, and fostering diversity, equity, and inclusion opportunities for future biopharma leaders. Lindsay Androski has been the CEO of the company since 2016. |
